Relationship Between Cardiopulmonary Exercise Testing and Ca-P in Chronic Kidney Disease (CKD)

Evaluation of the Relationship Between Cardiopulmonary Exercise Testing (CPET ) Abnormalities and Ca-P Status in CKD Stage3-5

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04013139

Enrollment

200

Registered

2019-07-09

Start date

2020-01-01

Completion date

2021-10-01

Last updated

2022-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ckd-Mbd

Brief summary

Reductions in exercise capacity associated with exercise intolerance augment cardiovascular disease risk and predict mortality in chronic kidney disease. This study utilized cardiopulmonary exercise testing to (a) investigate mechanisms of exercise intolerance; (b) unmask subclinical ca and p and vitamin D abnormalities that may precede cardiovascular disease in chronic kidney disease.

Detailed description

Cardiopulmonary exercise testing will carry out in Stage 3-5 chronic kidney disease patients ; estimated glomerular filtration rate \<60 ml/min/1.73 m2) and biochemistry will be added (Ca P Via D PTH FGF23).

Interventions

DIAGNOSTIC_TESTCPET

CPET

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* CKD Patients with GFR \<60 non-dialysis * age\<18

Exclusion criteria

* HTN * not signing consent * active coronary disease

Design outcomes

Primary

Measure	Time frame	Description
Calcium x phosphorus change in stage 3-5	12 MONTHS	CaxP change
CPET score change	12 MONTHS	Evaluation of CPET score change

Secondary

Measure	Time frame	Description
Renal Function change	12 MONTHS	GFR change

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026